SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Background Despite available interventions, people with type 2 diabetes (T2D) remain at
risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

OBJECTIVE To evaluate the prognostic value of glomerular hyperfiltration on long-term
kidney-related outcomes and mortality in patients with diabetes. RESEARCH DESIGN AND …

Aims The effects of adding a sodium–glucose cotransporter 2 (SGLT2) inhibitor to a
mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor–neprilysin inhibitor …

Aim In this subgroup analysis of STRONG‐HF, we explored the association between
changes in renal function and efficacy of rapid up‐titration of guideline‐directed medical …

Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post‐
initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the …

Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical
condition characterized by dyspnea and functional impairment. HFrEF has a high burden of …

Importance An initial decline in estimated glomerular filtration rate (eGFR) is expected after
initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed …